ArtVentive EOS(TM) Device Featured at GEST Conference in Seville, Spain

CARLSBAD, CA / ACCESSWIRE / July 8, 2015 / ArtVentive Medical Group, Inc. (OTCQB: AVTD) announced today that the Company’s Endoluminal Occlusion System (EOS(TM)) was featured in presentations at the Global Embolization Symposium and Technologies (GEST) conference in Seville, Spain.

Geert Maleux, Professor in the Department of Radiology at The University Hospital, Leuven, Belgium, presented his experience with the EOS(TM) device in spermatic vein applications for the treatment of varicoceles. While sharing images from these cases, Dr. Maleux said, “The EOS(TM) platform provides immediate occlusion of the target vessel. This is a significant step forward in embolization products that shows potential across a number of challenging arterial and venous applications.”

Leon Rudakov, President and CTO, commented: “We are excited for the delegates at the GEST conference to learn more about EOS(TM) clinical experience. GEST is a content rich environment where leaders in embolization gather to discuss new technologies and procedures. This is the perfect arena for further discussion of the EOS(TM) platform.”

About ArtVentive Medical Group, Inc.

ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is an innovative, multi-faceted medical device company focused on developing, manufacturing and marketing globally a family of devices.

The ArtVentive EOS(TM) platform is catheter-based, self-expandable and facilitates occlusion of peripheral body lumens, cavities occurring within the body’s vascular system and organ network. The ArtVentive EOS(TM) is designed to serve as an alternative to major surgery in certain cases. This technological innovation brings current interventional, image-guided techniques to a new level of sophistication, with the potential to resolve significant, unaddressed health issues.

The ArtVentive EOS(TM) proprietary technology platform provides a foundation for future innovation and has the potential to address indications in several clinical areas, including peripheral and neurological vascular disorders, women’s health (minimally invasive contraceptive and birth control), interventional cardiology, pulmonary and interventional oncology procedures.

More information about ArtVentive can be found at www.artventivemedical.com.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to the Company’s current expectations, projections and beliefs concerning matters that are not historical facts. Forward-looking statements are not guarantees of future performance. Forward-looking statements involve uncertainties, risks, assumptions and contingencies, many of which are outside the Company’s control, and, thus, actual results could differ materially from those described in or implied by any forward-looking statement. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. The Company assumes no obligation to update any forward-looking statement made in this news release that becomes untrue because of subsequent events, new information or otherwise, except to the extent it is required to do so in connection with the Company’s ongoing requirements under federal securities laws. For a further discussion of factors that could cause the Company’s future results to differ materially from any forward-looking statements, see the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission.

Contacts

ArtVentive Medical Group, Inc.
H.J. (Jim) Graham, Chief Executive Officer
Telephone: 760-471-7700
E-mail: hjgraham@artventivemedical.com

SOURCE: ArtVentive Medical Group, Inc.

ReleaseID: 430441